1. Janssen Pharmaceuticals, Inc. Prescribing information: INVOKANA®(canagliflozin) tablets, for oral use. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/204042s027lbl.pdf. Accessed January 25, 2019.
2. AstraZeneca Pharmaceuticals LP. Prescribing information: FARXIGA® (dapagliflozin) tablets, for oral use. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/202293s017lbl.pdf. Accessed January 25, 2019.
3. Boehringer Ingelheim Pharmaceuticals, Inc. Prescribing information: JARDIANCE® (empagliflozin) tablets, for oral use. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/204629s018lbl.pdf. Accessed January 25, 2019.
4. Merck Sharpe & Dohme Corp. Prescribing information: STEGLATRO™ (ertugliflozin) tablets, for oral use. Available at:https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209803s001lbl.pdf. Accessed January 25, 2019.
5. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes—a systematic review;Rådholm;Diabetes Res Clin Pract.,2018